Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Specialty & Advanced Pharmaceuticals

INK Edge Outlook

Mostly sunny as of September 01, 2019
For the latest outlook, get the company report
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 03, 2019 14:37 ET
Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets
Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today commented on the recent claims brought against various pharma companies in the United States and Canada (including against Joddes and Pharmascience, the Goodman family businesses in which Jonathan Goodman, Knight’s CEO, personally owns at least a 25% interest).
Read full article
Aug 26, 2019 08:00 ET
Israeli Courts Rule Against Knight Therapeutics’ and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison
Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), received a favorable ruling from Israeli courts in response to a frivolous and costly litigation claim brought by Knight CEO, Jonathan Goodman, against Medison in an attempt to silence Medison with respect to Knight’s lack of performance and poor corporate governance.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.95
--
--
Price to Sales - TTM
79.93
5.69
12.72
Price to Book - most recent quarter
1.06
1.06
2.78
Price to Cash Flow per share - TTM
26.95
26.95
12.38
Price to Free Cash Flow per share - TTM
--
--
18.61
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 20194,428,668276,885
Aug 15, 20194,151,783436,626
Jul 31, 20193,715,157486,341
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $GUD.CA

StockTwits